205 related articles for article (PubMed ID: 29063678)
1. Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor.
Whittaker SR; Barlow C; Martin MP; Mancusi C; Wagner S; Self A; Barrie E; Te Poele R; Sharp S; Brown N; Wilson S; Jackson W; Fischer PM; Clarke PA; Walton MI; McDonald E; Blagg J; Noble M; Garrett MD; Workman P
Mol Oncol; 2018 Mar; 12(3):287-304. PubMed ID: 29063678
[TBL] [Abstract][Full Text] [Related]
2. Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer.
Frame S; Saladino C; MacKay C; Atrash B; Sheldrake P; McDonald E; Clarke PA; Workman P; Blake D; Zheleva D
PLoS One; 2020; 15(7):e0234103. PubMed ID: 32645016
[TBL] [Abstract][Full Text] [Related]
3. AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9.
Cai D; Byth KF; Shapiro GI
Cancer Res; 2006 Jan; 66(1):435-44. PubMed ID: 16397259
[TBL] [Abstract][Full Text] [Related]
4. The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway.
Whittaker SR; Walton MI; Garrett MD; Workman P
Cancer Res; 2004 Jan; 64(1):262-72. PubMed ID: 14729633
[TBL] [Abstract][Full Text] [Related]
5. Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity.
Chen Z; Wang Z; Pang JC; Yu Y; Bieerkehazhi S; Lu J; Hu T; Zhao Y; Xu X; Zhang H; Yi JS; Liu S; Yang J
Sci Rep; 2016 Jul; 6():29090. PubMed ID: 27378523
[TBL] [Abstract][Full Text] [Related]
6. Xylocydine, a novel Cdk inhibitor, is an effective inducer of apoptosis in hepatocellular carcinoma cells in vitro and in vivo.
Cho SJ; Lee SS; Kim YJ; Park BD; Choi JS; Liu L; Ham YM; Moon Kim B; Lee SK
Cancer Lett; 2010 Jan; 287(2):196-206. PubMed ID: 19616371
[TBL] [Abstract][Full Text] [Related]
7. A novel series of highly potent 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitors.
Gucký T; Jorda R; Zatloukal M; Bazgier V; Berka K; Řezníčková E; Béres T; Strnad M; Kryštof V
J Med Chem; 2013 Aug; 56(15):6234-47. PubMed ID: 23829517
[TBL] [Abstract][Full Text] [Related]
8. Curcumin suppresses proliferation of colon cancer cells by targeting CDK2.
Lim TG; Lee SY; Huang Z; Lim DY; Chen H; Jung SK; Bode AM; Lee KW; Dong Z
Cancer Prev Res (Phila); 2014 Apr; 7(4):466-74. PubMed ID: 24550143
[TBL] [Abstract][Full Text] [Related]
9. A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration.
Heathcote DA; Patel H; Kroll SH; Hazel P; Periyasamy M; Alikian M; Kanneganti SK; Jogalekar AS; Scheiper B; Barbazanges M; Blum A; Brackow J; Siwicka A; Pace RD; Fuchter MJ; Snyder JP; Liotta DC; Freemont PS; Aboagye EO; Coombes RC; Barrett AG; Ali S
J Med Chem; 2010 Dec; 53(24):8508-22. PubMed ID: 21080703
[TBL] [Abstract][Full Text] [Related]
10. p27-Associated G1 arrest induced by hinokitiol in human malignant melanoma cells is mediated via down-regulation of pRb, Skp2 ubiquitin ligase, and impairment of Cdk2 function.
Liu S; Yamauchi H
Cancer Lett; 2009 Dec; 286(2):240-9. PubMed ID: 19631451
[TBL] [Abstract][Full Text] [Related]
11. The effects of the CDK inhibitor seliciclib alone or in combination with cisplatin in human uterine sarcoma cell lines.
Coley HM; Shotton CF; Kokkinos MI; Thomas H
Gynecol Oncol; 2007 May; 105(2):462-9. PubMed ID: 17300833
[TBL] [Abstract][Full Text] [Related]
12. Structure of cyclin-dependent kinase 2 (CDK2) in complex with the specific and potent inhibitor CVT-313.
Talapati SR; Nataraj V; Pothuganti M; Gore S; Ramachandra M; Antony T; More SS; Krishnamurthy NR
Acta Crystallogr F Struct Biol Commun; 2020 Aug; 76(Pt 8):350-356. PubMed ID: 32744246
[TBL] [Abstract][Full Text] [Related]
13. Cyclin-dependent kinase 9 activity regulates neutrophil spontaneous apoptosis.
Wang K; Hampson P; Hazeldine J; Krystof V; Strnad M; Pechan P; M J
PLoS One; 2012; 7(1):e30128. PubMed ID: 22276149
[TBL] [Abstract][Full Text] [Related]
14. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.
Kang J; Sergio CM; Sutherland RL; Musgrove EA
BMC Cancer; 2014 Jan; 14():32. PubMed ID: 24444383
[TBL] [Abstract][Full Text] [Related]
15. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1.
MacCallum DE; Melville J; Frame S; Watt K; Anderson S; Gianella-Borradori A; Lane DP; Green SR
Cancer Res; 2005 Jun; 65(12):5399-407. PubMed ID: 15958589
[TBL] [Abstract][Full Text] [Related]
16. The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis.
Whittaker SR; Te Poele RH; Chan F; Linardopoulos S; Walton MI; Garrett MD; Workman P
Cell Cycle; 2007 Dec; 6(24):3114-31. PubMed ID: 18075315
[TBL] [Abstract][Full Text] [Related]
17. Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor.
Albert TK; Rigault C; Eickhoff J; Baumgart K; Antrecht C; Klebl B; Mittler G; Meisterernst M
Br J Pharmacol; 2014 Jan; 171(1):55-68. PubMed ID: 24102143
[TBL] [Abstract][Full Text] [Related]
18. CDK2 regulates HIV-1 transcription by phosphorylation of CDK9 on serine 90.
Breuer D; Kotelkin A; Ammosova T; Kumari N; Ivanov A; Ilatovskiy AV; Beullens M; Roane PR; Bollen M; Petukhov MG; Kashanchi F; Nekhai S
Retrovirology; 2012 Nov; 9():94. PubMed ID: 23140174
[TBL] [Abstract][Full Text] [Related]
19. N-&-N, a new class of cell death-inducing kinase inhibitors derived from the purine roscovitine.
Bettayeb K; Sallam H; Ferandin Y; Popowycz F; Fournet G; Hassan M; Echalier A; Bernard P; Endicott J; Joseph B; Meijer L
Mol Cancer Ther; 2008 Sep; 7(9):2713-24. PubMed ID: 18790752
[TBL] [Abstract][Full Text] [Related]
20. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00.
Joshi KS; Rathos MJ; Joshi RD; Sivakumar M; Mascarenhas M; Kamble S; Lal B; Sharma S
Mol Cancer Ther; 2007 Mar; 6(3):918-25. PubMed ID: 17363486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
